The global allergy immunotherapy market is expected to show a significant growth rate during the forecast period. Allergy is hypersensitive to the body’s immune system towards several substances that include pollen, dust, and food. There are various types of allergies includes drugs, food, pollen, latex, and dust among others. As per the Food Allergy Research & Association (FARA), around 15 million people in the US have food allergies and approximately 4% of which is seen in the pediatrics and around more than 60% in adults. The introduction of new immunotherapy drugs and advancement in the treatment and medicine of allergyis the factor fueling the growth of the allergy immunotherapy market during the forecast period.
Browse the full report description of "Global Allergy Immunotherapy Market Size, Share & Trends Analysis Report by Type (Allergic Rhinitis, AllergicAsthma, Food Allergy, Drug Allergy, and Others), by Treatment (Subcutaneous Immunotherapy, Sublingual Immunotherapy), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/allergy-immunotherapy-market
The rising prevalence of allergies along with growing demand for the treatment of these diseases are motivating the key players of the allergy immunotherapy market to launch technologically advanced and cost-efficient treatment that can be affordable to the large pool of patients. The major market players are actively conducting strategic acquisitions, partnerships, and collaboration to increase their market presence and to gain a competitive edge. For instance, in April 2018, ALK had announced its partnership with Torii Pharmaceutical Co. Ltd. has agreed on a price with authorities and secured a listing on National health Insurance reimbursement for its sublingual allergy immunotherapy tablet against Japanese cedar allergy, brand name CEDAARCURE.
In January 2019, Sandoz, Inc. had announced the introduction of SYMJEPI (epinephrine) 0.3 mg injection for the treatment of allergic reactions (Type 1) in the emergency including anaphylaxis, allergen immunotherapy, drugs, diagnostics testing substance, foods as well as exercise-induced anaphylaxis. The company is introducing this medicine as areasonable, affordable, single-dose and prefilled syringe alternative to epinephrine auto-injectors. In February 2018, Aimmune therapeutics, Biopharmaceutical Company developing a treatment for food allergies, introduced its phase 3 European clinical trial of AR101 for the treatment of peanut allergy that named ARTEMIS met its efficacy endpoint required by the Food and Drug Administration (FDA).
Current Market Trends Covered in the Market Report
Global Allergy Immunotherapy Market- Segmentation
By Type
By Treatment
By Distribution Channel
Global Allergy Immunotherapy Market – Segment by Region
North America
Europe
Asia-Pacific
Rest of the World